Get the Stockscreener App
6.40
1.11%
0.07
Mimedx Group Inc stock is traded at $6.40, with a volume of 884.75K.
It is up +1.11% in the last 24 hours and down -7.65% over the past month.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
See More
Previous Close:
$6.33
Open:
$6.28
24h Volume:
884.75K
Relative Volume:
1.01
Market Cap:
$947.85M
Revenue:
$342.81M
Net Income/Loss:
$97.67M
P/E Ratio:
10.41
EPS:
0.6145
Net Cash Flow:
$50.46M
1W Performance:
-6.71%
1M Performance:
-7.65%
6M Performance:
+0.95%
1Y Performance:
-28.17%
1-Day Range:
$6.25
$6.415
1-Week Range:
$6.25
$6.93
52-Week Range:
$5.79
$9.362
Mimedx Group Inc Stock (MDXG) Company Profile
Name
Mimedx Group Inc
Sector
Industry
Phone
(770) 651-9100
Address
1775 W OAK COMMONS COURT, NE, MARIETTA
Compare MDXG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 6.49 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.83 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.82 | 418.21M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
7.30 | 329.86M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
48.05 | 0 | 0 | 0 | 0 | 0.00 |
|
QQQE
Direxion NASDAQ-100 Equal Weigh
|
105.25 | 0 | 0 | 0 | 0 | 0.00 |
Mimedx Group Inc Stock (MDXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-07-24 | Initiated | Lake Street | Buy |
| Oct-27-23 | Initiated | Craig Hallum | Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-26-21 | Initiated | Northland Capital | Outperform |
| Mar-19-21 | Initiated | H.C. Wainwright | Buy |
View All
Mimedx Group Inc Stock (MDXG) Latest News
MiMedx Group Inc Is Quietly Going Off: Is MDXG the Sleeper Stock You’re Sleeping On? - AD HOC NEWS
Institution Moves: Can MiMedx Group Inc stock continue upward trendCPI Data & Daily Market Momentum Tracking - moha.gov.vn
Harbor Capital Advisors Inc. Cuts Holdings in MiMedx Group, Inc $MDXG - MarketBeat
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel - Sahm
MiMedx Group Signs Exclusive Agreement to Distribute Regen Lab USA's RegenKit-Wound Gel in US - marketscreener.com
MiMedx (MDXG) Secures Exclusive Deal for U.S. Distribution of Re - GuruFocus
MiMedx signs exclusive U.S. distribution deal for RegenKit-Wound Gel - Investing.com
MiMedx signs exclusive U.S. distribution deal for RegenKit-Wound Gel By Investing.com - Investing.com South Africa
MiMedx Group, Inc. Partners with Regen Lab USA LLC to Distribute RegenKit®-Wound Gel in the U.S. - Quiver Quantitative
Mimedx Enters into Exclusive U.S. Distribution Agreement for Regenkit®?-Wound Gel - marketscreener.com
Value Recap: Why MiMedx Group Inc stock remains undervaluedWeekly Risk Report & Weekly Top Performers Watchlists - moha.gov.vn
Will MiMedx Group Inc. stock gain from lower inflationJuly 2025 Breakouts & Short-Term Trading Alerts - Улправда
With 47% stake, MiMedx Group, Inc. (NASDAQ:MDXG) seems to have captured institutional investors' interest - Yahoo Finance
MIMEDX reports immunomodulatory effects of placental allografts By Investing.com - Investing.com Australia
Will MiMedx Group Inc. stock deliver consistent dividendsJuly 2025 Retail & Expert Approved Momentum Ideas - Улправда
What risks investors should watch in MiMedx Group Inc. stockJuly 2025 Price Swings & Short-Term Trading Opportunity Alerts - DonanımHaber
MIMEDX reports immunomodulatory effects of placental allografts - Investing.com
MiMedx (MDXG) Highlights New Study Showcasing Immunomodulatory B - GuruFocus
MiMedx Group, Inc. Announces New Research Supporting Immunomodulatory Effects of Amniotic Membrane Allografts - Quiver Quantitative
MIMEDX Announces Publication in the Journal of Inflammation - GlobeNewswire
MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro - Sahm
Can MiMedx Group Inc. stock continue upward trendJuly 2025 Decliners & Weekly High Return Forecasts - DonanımHaber
Fundamentals Check: Can MiMedx Group Inc. stock maintain operating margins2025 Analyst Calls & Fast Entry Momentum Trade Alerts - ulpravda.ru
Can MiMedx Group Inc. stock maintain operating marginsSell Signal & Growth Oriented Trading Recommendations - Улправда
Mizuho Maintains MiMedx Group (MDXG) Outperform Recommendation - Nasdaq
MiMedx Group (NASDAQ:MDXG) Price Target Lowered to $10.00 at Mizuho - MarketBeat
MiMedx price target lowered to $10 from $12 at Mizuho - TipRanks
Analysts’ Top Healthcare Picks: Ligand Pharma (LGND), MiMedx Group (MDXG) - The Globe and Mail
Is MiMedx Group, Inc.'s (NASDAQ:MDXG) Recent Stock Performance Tethered To Its Strong Fundamentals? - simplywall.st
Divisadero Street Capital Management LP Boosts Stock Position in MiMedx Group, Inc $MDXG - MarketBeat
Trigran Investments Inc. Has $51.27 Million Holdings in MiMedx Group, Inc $MDXG - MarketBeat
MiMedx Group (MDXG) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Why MiMedx Group Inc. stock remains undervaluedWeekly Trade Analysis & Proven Capital Preservation Tips - Newser
How currency fluctuations impact MiMedx Group Inc. stockJuly 2025 Rallies & Intraday High Probability Alerts - Newser
Geode Capital Management LLC Decreases Stock Holdings in MiMedx Group, Inc $MDXG - MarketBeat
MiMedx announces publication of interim results from CAMPAIGN trial - MSN
MiMedx Group Inc. Reports Record Q3 Revenue - MSN
MiMedx Group (MDXG) Is Down 8.4% After Strong CAMPAIGN Trial Results for EPIEFFECT Product – What's Changed - simplywall.st
MiMedx Group (MDXG) Is Down 8.4% After EPIEFFECT’s Strong Interim Trial Data Outshines Standard Care - Yahoo Finance
Is MiMedx Group Inc. stock attractive for long term wealth building - newser.com
Is MiMedx Group Inc. stock a good choice for value investors2025 Retail Activity & Weekly Stock Breakout Alerts - newser.com
Will MiMedx Group Inc. stock maintain dividend yieldFed Meeting & Smart Money Movement Tracker - newser.com
Can MiMedx Group Inc. stock sustain market leadershipJuly 2025 Action & Technical Pattern Based Buy Signals - newser.com
Is MiMedx Group Inc. showing signs of accumulationVolume Spike & Pattern Based Trade Signal System - newser.com
Will MiMedx Group Inc. stock go up soon2025 Historical Comparison & Risk Managed Trade Strategies - newser.com
Mimedx Group Inc Stock (MDXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):